Nerve growth factor in rat glioma cells

Identification of potential therapeutic targets for gliomas by bioinformatics analysis

Gliomas are primary tumors that originate in the brain or spinal cord and develop from supportive glial cells. The present study aimed to identify potential candidate molecular markers for the treatment of gliomas, and to explore the underlying mechanisms of this disease. The gene expression profile data GSE50021, which consisted of 10 specimens of normal brain tissues and 35 specimens of glioma tissues, was downloaded from Gene Expression Omnibus (GEO). The methylation microarray data GSE50022, consisting of 28 glioma specimens, was also downloaded from GEO. Differentially expressed genes (DEGs) between patients with glioma and normal individuals were identified, and key methylation sites were screened. Transcriptional regulatory networks were constructed, and target genes were selected. Survival analysis of key methylation sites and risk analysis of sub-pathways were performed, from which key genes and pathways were selected. A total of 79 DEGs and 179 key methylation sites were identified, of which 20 target genes and 36 transcription factors were included in the transcriptional regulatory network. Glutamate metabotropic receptor 2 (GRM2) was regulated by 8 transcription factors. Inositol-trisphosphate 3-kinase A (ITPKA) was a significantly enriched DEG, associated with the inositol phosphate metabolism pathway, Survival analysis revealed that the survival time of patients with lower methylation levels in cg00157228 was longer than patients with higher methylation levels. ITPKA was the closest located gene to cg00157228. In conclusion, GRM2 and enriched ITPKA, associated with the inositol phosphate metabolism pathway, may be key mechanisms in the development and progression of gliomas. Furthermore, the present study provided evidence for an additional mechanism of methylation-induced gliomas, in which methylation results in the dysregulation of specific transcripts. The results of the present study may provide a research direction for studying the mechanisms underlying the development and progression of gliomas.

The effect of the platelet derived wound healing formula and the nerve growth factor on the experimentally injured spinal cord

The main purpose of this study is to investigate the effect of platelet derived wound healing formula (PDWHF) and nerve growth factor (NGF) in the treatment of experimental spinal cord injury. PDWHF is a conglomerate of growth factors which include platelet derived growth factor (PDGF), platelet derived angiogenesis factor (PDAF), transforming growth factor-beta (TGF beta) and platelet factor IV (PF4). Complete spinal cord transection was performed at T12 in rats and the treatment of the spinal cord injury was achieved by filling the dead space with type 1 collagen gel impregnated with PDWHF, or with 2.5S-NGF. Controls were treated with only type 1 collagen gel. Animals were sacrificed at 1, 2 or 3 months. Histopathologically, tissue autolysis and cavity formation by phagocytosis expanded 1-3 mm into the cord stumps and the volume of cavitation was less in the two treated groups. In the NGF group, a greater number of surviving nerve cells were observed in this region. Most of the control animals formed only thin, short axonal bundles, however, increased axonal regrowth was noted in animals treated with trophic factors, especially in the NGF group. The NGF group formed thick axonal bundles and abundant neuroma. Increased angiogenesis was observed in the collagen gel matrix and the injured spinal cord parenchyma, in the PDWHF group. Recent studies have shown that mammalian adult CNS possesses the ability for structural and/or functional plasticity following injury under appropriate circumstances. In this in vivo study, exogenous NGF appeared to induce axomal outgrowth and nerve cell survival. PDWHF produced notable angiogenesis which seemed to improve the extracellular microenvironment. This may be important for the delivery of exogenous trophic factors, nutrients and for the changes of extracellular matrices to support nerve cells and axons.

Glial receptors and their intervention in astrocyto-astrocytic and astrocyto-neuronal interactions

As shown on cultured astrocytes from the mouse, in the presence of adenosine deaminase, 2-chloroadenosine by acting on A1-adenosine receptors potentiated the activation of phospholipase C induced by the alpha 1-adrenergic agonist, methoxamine. This potentiation required the presence of external calcium and was blocked by pertussis toxin. Moreover, this potentiation resulted from a cascade of events: activation (by calcium and protein kinase C) of a phospholipase A2 coupled to A1-adenosine receptors, release of arachidonic acid, which inhibited the reuptake of glutamate into astrocytes and finally additional activation of phospholipase C by externally accumulated glutamate through metabotropic receptors. The effects of 2-chloroadenosine and methoxamine were respectively mimicked by somatostatin and substance P while endothelins reproduced the combined effects of 2-chloroadenosine and methoxamine. Conditioned media from treated astrocytes enriched in glutamate stimulated phospholipase C in cultured striatal neurones. In addition, glutamate alone was also found to stimulate phospholipase A2 in astrocytes through receptors exhibiting a pharmacological profile distinct from metabotropic receptors coupled to phospholipase C and the glutamate response was potentiated by ATP. Moreover, the neuronal arachidonic acid production evoked by glutamate was potentiated by acetylcholine. Finally, the combined application of 2-chloroadenosine and methoxamine on striatal astrocytes reduced the permeability of gap junctions between astrocytes and this response was mimicked by arachidonic acid. Together, these results emphasized the contribution of astrocytes in the regulation of glutamatergic transmission.

Neurotrophin gene expression by cell lines derived from human gliomas

The expression of neurotrophin (NGF, BDNF, and NT-3) mRNAs in 24 cell lines derived from human malignant gliomas was studied by Northern analysis. Widespread expression of neurotrophin genes was found with BDNF being the most abundantly expressed. Nearly all cell lines expressed BDNF, and about two-thirds of the cell lines expressed NGF and NT-3. Half of the cell lines analyzed expressed all three neurotrophins. Secretion of NGF into the medium of several cell lines could be detected by ELISA and a PC12 neurite outgrowth assay. Immuno- and bioactive NGF was isolated from conditioned medium of one cell line. No evidence of expression of the neurotrophin receptors trk and trkB by Northern analysis was found. Receptor crosslinking with radiolabeled cognate ligands failed to detect functional receptors in all but one cell line. In this cell line a receptor complex for BDNF was found that corresponded to truncated trkB receptors that lack the signal transducing tyrosine kinase domain. Neurotrophins did not stimulate mitosis of the glioma cultures. The findings suggest that production of neurotrophins by glioma cells is a general phenomenon, although neurotrophins made by gliomas lacking their receptors may not play an autocrine but rather a paracrine role.

Growth factors and carcinoid tumours

The presence of growth factors and their receptors in human midgut carcinoids and in gastric carcinoids of Mastomys have been investigated. Human midgut carcinoid tumours produce IGF-I as demonstrated by immunocytochemistry and radioimmunoassay. IGF-I receptors were detectable in half of the tumours and stimulation of cultured tumour cells with IGF-I enhanced DNA synthesis. IGF-I may therefore act as an autocrine stimulator of carcinoid tumour growth. Expression of TGF-alpha and EGF-receptors could also be demonstrated in midgut carcinoids by immunocytochemistry and Northern analysis, suggesting that TGF-alpha participates in the autocrine modulation of carcinoid growth. Co-culture of human midgut carcinoid tumours and rat fetal cholinergic neurons demonstrated secretion of a potent neuronotrophic factor by cultured tumour cells. IGF-I and TGF-alpha may account for these neuronotrophic effects, but carcinoid tumours may also secrete an as yet unidentified growth factor. Gastric (ECL cell) carcinoids developed rapidly in Mastomys during hypergastrinemia due to histamine2-receptor blockade, suggesting that gastrin is an essential growth factor for these carcinoids.

Production of transferable neuronotrophic factor(s) by human midgut carcinoid tumour cells; studies using cultures of rat fetal cholinergic neurons

A co-culture system was established between human midgut carcinoid tumour cells and rat fetal cholinergic neurons. In monocultures in serum-free media, only tumour cells survived, while neurons deteriorated. In serum-free co-cultures, neurons displayed outgrowth of neuritic processes. Neurons of neuronal serum-free monocultures thrived if supplemented with conditioned media from tumour cell cultures grown serum-free. This indicates that tumour cells produce transferable growth factor(s) with potent neuronotrophic actions. Immunocytochemical studies indicate that this growth factor resembles nerve growth factor immunologically, since tumour cells were strongly immunoreactive after incubation with a rabbit anti-nerve growth factor antiserum, and furthermore expressed immunoreactive nerve growth factor receptors.

Expression of high molecular weight astroglial extracellular proteins is altered by growth environment

Conditioned medium from primary rat cortical glia was analyzed with respect to the composition of the secreted high molecular weight protein species. Developmental characteristics of astroglia are affected by growth in the presence and absence of serum. These growth conditions had a pronounced effect on the extracellular protein profile, cellular morphology, and cell substratum adhesion. Cells cultured in defined serumless medium did not express certain proteins expressed in the presence of serum but rather synthesized proteins specifically stimulated by the defined serumless environment. A morphological change from flat amorphous to a contracted fibrous network having an increased affinity for self-self cellular adhesion rather than adhesion to the surface of the tissue culture dish was also stimulated by the defined serumless medium environment. A comparison of the extracellular proteins secreted by the rat C6 glioma and the rat PC12 cell demonstrated the cell-specific nature of the primary glial proteins.

Expression of the beta-nerve growth factor gene in hippocampal neurons

In situ hybridization with complementary DNA probes for nerve growth factor (NGF) was used to identify cells containing NGF messenger RNA in rat and mouse brain. The most intense labeling occurred in hippocampus, where hybridizing neurons were found in the dentate gyrus and the pyramidal cell layer. The neuronal identity of NGF mRNA-containing cells was further assessed by a loss of NGF-hybridizing mRNA in hippocampal areas where neurons had been destroyed by kainic acid or colchicine. RNA blot analysis also revealed a considerable decrease in the level of NGF mRNA in rat dentate gyrus after a lesion was produced by colchicine. This lesion also caused a decrease in the level of Thy-1 mRNA and an increase in the level of glial fibrillary acidic protein mRNA. Neuronal death was thus associated with the disappearance of NGF mRNA. These results suggest a synthesis of NGF by neurons in the brain and imply that, in hippocampus, NGF influences NGF-sensitive neurons through neuron-to-neuron interactions.

Neuronotrophic factors released by C6 glioma cells

Glial cells have been shown previously to release factors that promote survival of central and peripheral neurons [neuronotrophic factors (NTFs)]. We have investigated the release of NTFs by C6 cells, a rat glioma cell line, under different modes of conditioning. Media conditioned in the presence or absence of serum [C6 cell conditioned media (C6CMs)] were analyzed using biological, biochemical, and immunological assays. We report that (a) nuclear and cytoskeletal proteins were not present in C6CMs, indicating that C6CM proteins result from release by C6 cells rather than from cell death; (b) C6CM contained 1-3 micrograms protein/ml, corresponding to a secretion rate of about 0.5 pg protein per cell and day; (c) C6CM contained the neurite-promoting factor laminin and low amounts of nerve growth factor; (d) the presence of fetal calf serum in the culture medium was essential for synthesis and release of NTFs; and (e) our C6CM contained at least three NTFs differing by their temporal secretory patterns and three NTFs differing by biochemical properties, indicating that C6 cells produce and secrete six different NTFs. Within these, nerve growth factor seems to be the only established NTF.

Nerve growth factor (NGF) receptor expression in chicken cranial development

In order to map the expression of receptors for nerve growth factor (NGF) during brain and cranial ganglia development, iodinated NGF (125I beta NGF) was used as a probe in an autoradiographical analysis performed between embryonic day 3 (E3) and posthatching day 3 (P3) of chicken development. Heavy autoradiographic labelling was observed at the classical NGF target sites, the proximal cranial sensory ganglia and the sympathetic superior cervical ganglion, throughout development and after hatching. In contrast, only weak labelling could be detected during a restricted time span in the vestibulocochlear (E4-E8) and the distal cranial sensory ganglia (E4-E10), the neurons of which originate from the otic and epibranchial placodes. Specific 125I beta NGF binding was also observed in various brain regions during early brain development. NGF receptor expression there followed a characteristic pattern. The neuroepithelial layer displayed very low levels of specific 125I beta NGF binding, while strong 125I beta NGF labelling was found in the mantle layer. Brainstem somatomotor nuclei, visceromotor columns, brainstem alar plate, cerebellar anlage, tectum, and basal forebrain (epithalamus, striatum) were found to be transiently labelled by 125I beta NGF in early development (E4-E12). Non-nervous tissues such as parts of the otic vesicle epithelium and skeletal muscle anlagen of the head were also labelled. These results, showing specific binding of 125I beta NGF to cranial cells of different origin (neural tube, neural crest, placode, and possibly mesoderm) strengthen the concept that NGF may have diverse functions in growth and differentiation of various tissues and cell types.

[3H]5-hydroxytryptamine binding to brain astroglial cells: differences between intact and homogenized preparations and mature and immature cultures

[3H]5-hydroxytryptamine ([3H]serotonin) binds with high affinity (KD 2-12 nM) to a finite number of sites on brain astroglial cells. The number of binding sites in the C6 glioma line is decreased significantly (Bmax = 315 versus 30 fmol/mg) by homogenization. In intact primary cultures, derived from newborn rat brain, the number of binding sites is far greater in cultures of immature astrocytes than in cultures treated with dibutyryl cyclic AMP (Bmax = 1,520 versus 580 fmol/mg). A role for these receptors in development is suggested.

Nerve growth factor in medium conditioned by embryonic chicken heart cells

The present report demonstrates that embryonic chicken heart cells in culture release different nerve growth promoting factors to their culture medium, one which is biologically and immunologically similar to mouse gland beta NGF. Serum-free heart cell conditioned medium thus promoted neurite outgrowth from sympathetic and ciliary ganglia and supported survival of dissociated ciliary neurons. The addition of affinity purified antibodies against mouse beta NGF does substantially but not completely inhibit the fibre outgrowth from sympathetic ganglia, but does not to any extent diminish the effects on the parasympathetic neurons. The chicken NGF recovered from polyacrylamide gels after electrophoresis greatly enhanced sympathetic fibre outgrowth, an activity completely suppressive by anti-beta NGF antibodies. We conclude that a chicken NGF is being produced by the embryonic heart cells in culture, and that this factor may be produced also in the embryo to fulfill a role in heart innervation.

Nerve growth factor synthesized by mouse fibroblast cells in culture: absence of alpha and gamma subunits

Nerve growth factor (NGF) is found in high concentrations in the mouse salivary gland. However, this gland is unique since salivary glands from other animals have only trace amounts of NGF. In the mouse gland, two high molecular weight forms of NGF have been reported, 7S-NGF [Varon, S., Nomura, J., & Shooter, E.M. (1967) Biochemistry 6, 2202-2209] and NGF1 [Young, M., Saide, J.D., Murphy, R.A., & Blanchard, M.H. (1978) Biochemistry 17, 1490-1498]. 7S-NGF is comprised of three noncovalently associated subunits: beta-NGF, which is the biologically active subunit, alpha subunit, and gamma subunit. A similar subunit composition is seen with NGF1 (unpublished work with R.A. Murphy). Since the mouse salivary gland is unique with regard to its synthesis of NGF, the following question arises. Do other sources of NGF produce either 7S-NGF or NGF1? Mouse fibroblast cells (L929) in culture synthesize and secrete into their feeding medium (conditioned medium) a beta-NGF-like molecule [Pantazis, N.J., Blanchard, M.H., Arnason, B.G.W., & Young, M. (1977) Proc. Natl. Acad. Sci. U.S.A. 74, 1492-1496]. These cells therefore provided the opportunity to examine the molecular nature of NGF produced by a nonsalivary gland source. In this study, it was determined by radioimmunoassay that neither the alpha nor the gamma subunit is present in fibroblast cell conditioned medium. Since alpha- and gamma-proteins are present in both 7S-NGF and NGF1, this indicates that neither of the salivary gland forms of NGF are produced by the mouse fibroblast cell.

Evidence for a motor nerve growth factor

We review the evidence that a motor nerve growth factor released from muscle has wide ranging effects on the development and maintenance of muscle innervation. The actions of this putative factor on motor neurons are analogous to the actions of the well known nerve growth factor (NGF) on sympathetic and sensory neurons.

Nerve growth factor and neural oncology

The precise role of the nerve growth factor protein (NGF) during the growth and development of the human nervous system is not determined. Although it appears to influence a number of neural functions, its mechanism of action is poorly understood. A number of researchers have proposed that NGF may be involved in several pathological conditions including cancer. It has been shown that NGF is secreted by certain sarcoma (23), neuroblastoma (113), and glioma (7,102,136) cell lines and can bind to neuroblastoma and metastatic melanoma cell lines (42). Neuroblastoma (136,181) and pheochromocytoma (165) cells in vitro can be induced by NGF to differentiate toward a morphologically "more benign" state and appropriate NGF treatment of rats can reduce the number of chemically induced gliomas and neurinomas (174,178). NGF can also reduce the growth of intracerebrally inoculated anaplastic glioma cells (172). Anti-NGF treatment of rats (178) and mice (179) can alter the tumor distribution observed following ethylnitrosourea or benzo(a)pyrene treatment (10). In humans, it has been reported that serum levels of NGF are usually elevated in persons "at risk" for neurofibromatosis (156). The precise nature of the NGF role is not known in these instances. Further understanding of the action of NGF could be of clinical importance.

Products of cultured neuroglial cells. III. Release of an 85,000 molecular weight glycoprotein by C6 glioma cells in vitro

With [3H]fucose as a marker, C6 glioma cells in culture released an 85,000 molecular weight molecule into the medium as the major extracellular glycoprotein. The quantity and extracellular/cytoplasmic ratio of this glycoprotein suggest that its cellular processing is different from that of five other released glycoproteins of molecular weights 55,000, 115,000, 130,000, 150,000, and 170,000. Nearly 40% of newly synthesized glycoproteins in the cells was released into the culture medium. Major glycoproteins retained by the cells migrated electrophoretically to molecular weight positions of 82,000, 110,000, 120,000, 140,000, and 160,000, and approximately one-third of these returned glycoproteins were labile to trypsinization. Both synthesis and release of these macromolecules were inhibited more than 95% with cycloheximide treatment, demonstrating that nearly all fucosylation was linked to protein synthesis. Since 40% of all glycoproteins was released under conditions of more than 99% cellular viability, it is likely that these extracellular glycoproteins are physiological products of membrane turnover and secretion, but not of cell lysis. The results provide a basis for the further study of glial differentiation and of shed glioma antigens.

Effect of nerve growth factor producing cells on anaplastic glioma and pheochromocytoma clones: involvement of other factors

When the NGF-secreting C-6 rat glioma cells were intracerebrally injected with F98 rat anaplastic glioma cells into rats syngeneic for the F98 cells, an increased mean survival time was observed for rats developing tumors compared with those injected with only anaplastic glioma cells. Thirty percent of the rats injected with both cell types showed no signs of tumor at 90 days. Pretreatment of the anaplastic glioma cells with conditioned medium of C-6 cells did not duplicate these results unless the C-6 cells were pretreated with 17 beta-estradiol, which appears to induce secretion of an adhesion factor as well as NGF. These rats survived even longer and 33% were free of tumors at 90 days. Histological examination of tumors of the nonsurviving rats revealed that they were basically well differentiated with only small anaplastic areas remaining. Both NGF and conditioned medium from C-6 and another NGF-secreting line, S-180 mouse sarcoma, induce process formation in F98 cells and in PC12 pheochromocytoma cells, but the processes that appear following NGF exposure are morphologically different from those induced by conditioned medium. Conditioned -medium-treated cells also have a flatter appearance. In F98 cells, NGF takes longer to induce processes than does conditioned medium. The NGF-induced effects observed in both cells are neutralized by anti-NGF IgG, but those induced by conditioned media are not. Nerve growth factor (NGF) induced increased adhesiveness in F98 rat anaplastic glioma and PC12 rat pheochromocytoma cells. Conditioned media are not. Nerve growth factor induced increased adhesive-and PCuced effects observed in both cells are neutralized by anti-NGF IgG, but those induced by conditioned media are not. Nerve growth factor (NGF) induced increased adhesiveness in F98 rat anaplastic glioma and PC12 rat pheochromocytoma cells. Conditioned media are not. Nerve growth factor induced increased adhesive-and PCuced effects observed in both cells are neutralized by anti-NGF IgG, but those induced by conditioned media are not. Nerve growth factor (NGF) induced increased adhesiveness in F98 rat anaplastic glioma and PC12 rat pheochromocytoma cells. Conditioned media are not. Nerve growth factor induced increased adhesive-and PC12 cells. Anti-NGF IgG did not influence this effect on F98 cells and only partially neutralized the effect on PC12 cells, indicating that other factors may be operative in this system. Conditioned medium collected from C-6 cells pretreated with 17 beta-estradiol induced the highest degree of adhesiveness observed in both F98 and PC12 cells, and this action was unaffected by anti-NGF IgG in either case. Conditioned media from other cell lines, a variety of selected proteins, and dBcAMP did not induce increased adhesiveness. The factor responsible for this effect is nondialyzable, heat-sensitive, and ammonium-sulfate-precipitable, and its secretion appears to be stimulated by 17 beta-estradiol.

Trophic interactions between astroglial cells and hippocampal neurons in culture

Astroglial cells in primary culture release factors into the medium that promote the growth and prolong the survival of rat hippocampal neurons in vitro.

Role of nerve growth factor in ethylnitrosourea-induced neural carcinogenesis

The sensitivity of the rat nervous system to malignant transformation by ethylnitrosourea (ENU) is a function of age at treatment. From late gestation, nervous structures decrease in sensitivity with age as non-neural structures increase in susceptibility. There is a decrease in the proportion of neural tumors induced by ENU and an increase in survival time when nerve growth factor (NGF) levels are elevated in the fetal or neonatal stage. If antibodies directed against mouse beta-NGF (anti-NGF) are administered prior to neonatal ENU treatment, neural tumors appear earlier, although in the same proportion as with treatment by ENU alone. This effect is not observed if the ENU is administered first. This phenomenon seems to be attributed to an increased number of trigeminal nerve neurinomas, which have a shorter latent period than other nervous system tumors. The induced neurological tumors in rats treated neonatally with anti-NGF prior to ENU seem to be almost exclusively neurinomas in the peripheral nervous system. Fetal anti-NGF treatment leads to an increased number of intracerebral gliomas and a longer survival time, which corresponds to the longer latent period of these tumors. The role of NGF in the sensitivity of the rat nervous system to carcinogenesis by ENU and its possible implications in the development of the nervous system discussed.

Somatomedins and other serum growth factors: a review of current concepts

Growth hormone is essential for sustaining longitudinal growth in man. However, during the last 20 years, it has become evident that the actions of growth hormone, at a cellular level, are mediated by specific growth promoting factors. This paper describes the nature and actions of mammalian growth factors and summarises the immense contribution that the measurement of these substances has made towards the elucidation of many problems in the science of human growth and development.

Regulation of nerve growth factor content in C6 glioma cells by beta-adrenergic receptor stimulation

The C6 glioma cell line contains nerve growth factor (NGF) which can be released into the medium. Treatment of the cells with beta-adrenoceptor agonists resulted in increased content of NGF in both the cells and the medium within a few hours, whereas alpha-adrenoceptor agonists were ineffective. The response was blocked by beta- but not alpha-adrenoceptor antagonists. The increase of the NGF content of glioma cells appeared to be mediated by an elevation of cyclic AMP or GMP. The addition to the cell cultures of other putative neurotransmitters failed to change the content of either NGF or cyclic AMP. These results are discussed with respect to a model for adrenergic neuron-glial interactions.

Secretion of nerve growth factor by central nervous system glioma cells in culture

Bacteriophage immunoassays, radioimmunoassays, and biological assays have been used to measure levels of NGF in media conditioned by rat C-6 glioma cells in culture. By all three criteria, these cells secrete a macromolecule which is indistinguishable from mouse submandibular gland NGF.

Metabolism of biogenic amines in neuroblastoma and glioma cells in culture

The kinetic parameters of monoamine oxidase (MAO; E.C 1.4.3.4) and catechol-O-methyltransferase (COMT; EC 2.1.1.6) were evaluated in extracts of adrenergic and non-adrenergic mouse neuroblastoma cells and in rat glioma cells. Using the naturally-occurring substrates tyramine, tryptamine, serotonin and norepinephrine, the affinity of MAO for a given substrate was independent of the presence of the catecholaminergic pathway or cell type used, with apparent Km values ranging from 8-14 microM for tryptamine to 510-580 microM for norepinephrine. The MAO activity in glioma cells was substantially greater than in either neuroblastoma clone, but Vmax values varied little with substrate among cell lines. Both the neuronal and glial COMT had a similar Km for 1-norepinephrine (200 microM); the corresponding Vmax values were also similar among the different cell lines, but represented only 2-10% of the maximal MAO activity. Neuroblastoma and glioma cells, when grown from early logarithmic to stationary phase, showed no significant changes in specific activity of either MAO or COMT. Growth of cells for 3 days with 1 mM-N6,O2'-dibutyryl adenosine-3',5'-cyclic monophosphate resulted in no marked change in either MAO or COMT activity. These results suggest that in neurons neither MAO nor COMT plays a major role in the type of transmitter inactivation that is analogous to that of acetylcholinesterase in cholinergic synapses. The occurrence of considerable MAO and acetylcholinesterase activities in glioma cells may indicate a role for these cells in neurotransmitter inactivation.

Immunocytochemical localization of nerve growth factor (NGF) in the submandibular gland of adult mice by light and electron microscopy

Nerve growth factor (NGF) was localized in the submandibular gland of adult male mice by a direct immunocytochemical method using highly purified antibodies against NGF coupled to horseradish peroxidase. In light microscopic sections the reaction product was entirely confined to the cells of the secretory tubules. The acinar part of the gland was free of reaction product. This finding was confirmed by electron microscopy. Within the cells NGF was localized exclusively in the apical secretory granules. No reaction was observed in the rough endoplasmic reticulum, the Golgi region or in the granules of the basal part of the cells. This observation favours the assumption that NGF is derived from a precursor molecule and that the precursor is transformed into immunologically active NGF within the secretory granules during their transport from the basal to the apical part of the tubular cells. Stimulation of the submandibular gland with carbachol (2 mg/kg) led to a massive release of the content of the secretory granules, including NGF, into the salivary duct.

Secretion of a nerve growth factor by mouse neuroblastoma cells in culture

Analyses of supernatant solutions from mouse C1300 neuroblastoma cultures by two independent immunoassays reveal that these cells secrete a factor which is immunochemically similar to mouse submaxillary gland nerve growth factor. The neuroblastoma factor is also biologically active in inducing neurite outgrowth from embryonic sensory ganglia-an effect that is completely blocked by specific antibody to nerve growth factor. Neuroblastoma cells are known to be functionally responsive to nerve growth factor, and the observation that they secrete a molecule like it may mean that these cells require or utilize the factor during growth in culture.